COMPANY

Eureka Therapeutics

HQ: Emeryville, CA source · eurekatherapeutics.com ↗

Keywords: oncology cancer solid tumors antibody Hepatocellular Carcinoma Liver Neoplasm Metastatic Liver Cancer Liver Cancer Adult Liver Cancer Hepatoblastoma B-Cell Lymphoma Lymphomas Non-Hodgkin's B-Cell ET190L1 ARTEMIS™ T cells ECT204 T cells ET140203 T Cells ET140203 autologous T cell product ET140202 autologous T cell product

Location: Emeryville, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

Jul 19, 2022 Trial start Phase 1/Phase 2: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma source ↗
Mar 11, 2022 Trial start Phase 1/Phase 2: GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC source ↗
Apr 14, 2021 Trial start Phase 1: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) source ↗
May 30, 2019 Trial start Phase 1: Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma source ↗
Apr 4, 2018 Trial start Phase 1: Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma source ↗
Sep 9, 2017 Trial start Phase 1: Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma source ↗

Upcoming milestones

Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC · NCT04864054
Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma · NCT04634357

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT04864054	GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC	Phase 1/Phase 2	Recruiting	Mar 11, 2022	Dec 31, 2027 (estimated)
NCT04634357	ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma	Phase 1/Phase 2	Recruiting	Jul 19, 2022	Dec 31, 2027 (estimated)
NCT04502082	Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)	Phase 1	Terminated	Apr 14, 2021	Aug 30, 2024 (actual)
NCT03998033	Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma	Phase 1	Terminated	May 30, 2019	Dec 31, 2020 (actual)
NCT03415399	Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma	Phase 1	Completed	Sep 9, 2017	Dec 31, 2020 (actual)
NCT03379493	Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma	Phase 1	Terminated	Apr 4, 2018	Dec 23, 2018 (actual)